Efficacy News and Research

RSS

Study provides first empirical evidence that foreign aid can greatly improve foreign public opinion

A study by Dartmouth and Australian researchers provides the first empirical evidence using data from a variety of countries that foreign aid can greatly improve foreign public opinion of donor countries.

12 Feb 2014

MIT develops robot that may speed up drug development for stroke patients

The development of drugs to treat acute stroke or aid in stroke recovery is a multibillion-dollar endeavor that only rarely pays off in the form of government-approved pharmaceuticals.

12 Feb 2014

Study shows dye brilliant blue G may improve recovery from traumatic brain injuries

A close cousin of the dye that makes fabric, M&M's and sports drinks blue may improve recovery from traumatic brain injuries.

12 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients.

11 Feb 2014

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD).

11 Feb 2014

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia (AML), to promote progression of the disease.

11 Feb 2014

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.

11 Feb 2014

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced positive safety results from a Phase I multiple ascending dose study of AVI-7288 in healthy volunteers.

10 Feb 2014

NASA signs patent to develop novel biotechnology approaches that could have medical applications

NASA has signed two patent license agreements with GRoK Technologies LLC of Houston to help develop novel biotechnology approaches that could have multiple applications in space and on Earth.

10 Feb 2014

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.

10 Feb 2014

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

10 Feb 2014

Researchers evaluate feasibility of using stem cell therapies on preterm infants to treat BPD

Advances in neonatal care for very preterm infants have greatly increased the chances of survival for these fragile infants. However, preterm infants have an increased risk of developing bronchopulmonary dysplasia (BPD), a serious lung disease, which is a major cause of death and lifelong complications.

6 Feb 2014

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

5 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy, according to a study published online in Circulation, the journal of the American Heart Association.

From Quest Diagnostics 5 Feb 2014

Bioengineer receives $1.4M grant to create nanoparticle system to shore up arterial walls

A UT Arlington bioengineer has received a four-year, $1.4 million National Institutes of Health grant to create a nanoparticle system to shore up arterial walls following angioplasty and stenting procedures to treat coronary arterial disease.

5 Feb 2014

New drug treatment effective against chronic pain caused by nerve damage post shingles

A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

5 Feb 2014

Psoriasis registry: an interview with Dr. Andrew D. Robertson, Chief Scientific and Medical Officer, National Psoriasis Foundation

Psoriasis is the most common autoimmune disease in the US, affecting 2 to 3% of all Americans. What causes psoriasis in any one individual will stem from a mixture of their genetic background and their environment.

4 Feb 2014

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.

4 Feb 2014

Efficacy News and Research

Study provides first empirical evidence that foreign aid can greatly improve foreign public opinion

MIT develops robot that may speed up drug development for stroke patients

Study shows dye brilliant blue G may improve recovery from traumatic brain injuries

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

NASA signs patent to develop novel biotechnology approaches that could have medical applications

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

pSivida announces financial results for second quarter 2014

Researchers evaluate feasibility of using stem cell therapies on preterm infants to treat BPD

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Bioengineer receives $1.4M grant to create nanoparticle system to shore up arterial walls

New drug treatment effective against chronic pain caused by nerve damage post shingles

Psoriasis registry: an interview with Dr. Andrew D. Robertson, Chief Scientific and Medical Officer, National Psoriasis Foundation

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News